Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2011-01-21 Director's Dealing
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2011-01-21 English
REGISTRATION STATEMENT ON FORM S-8 OF NOVARTIS AG
Regulatory Filings Classification · 100% confidence The document is a Registration Statement on Form S-8 filed with the SEC by Novartis AG. Form S-8 is used for registering securities to be offered under employee benefit plans, such as stock incentive plans. The document includes details about the securities to be registered, the registration fee, incorporation by reference of other filings, indemnification of directors and officers, and signatures of company officers. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length is substantial (15,000 characters), and it is not merely an announcement of a report but a full registration statement filing.
2011-01-18 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily consists of an investor relations press release announcing the start of a phase II clinical trial for a biosimilar drug by Sandoz, a division of Novartis. There are no financial statements, detailed financial data, or comprehensive management discussion and analysis present. The document is about a corporate announcement related to clinical trial progress and product development, not a financial report or regulatory certification. The length is under 10,000 characters and it serves as a communication to investors and the SEC about a business development event. This fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories such as earnings releases, annual reports, or management reports.
2011-01-10 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is an investor relations press release announcing a new indication approval for the drug Lucentis in the EU. It contains detailed information about clinical trial results, drug approval, and forward-looking statements. There are no financial statements or comprehensive financial data presented, nor is this an annual or quarterly report. The document is not a transcript, audit report, or management change announcement. It is a regulatory announcement providing material information to investors about a product development and regulatory approval. Form 6-K filings typically fall under Regulatory Filings (RNS) as they are periodic reports submitted by foreign private issuers to disclose material information. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (13,658 characters) and detailed content confirm it is not a mere announcement of a report but a substantive regulatory filing.
2011-01-07 English
Regulatory Filings 2011
Regulatory Filings
2011-01-05 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis International AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is an investor relations release announcing the European Commission approval of the drug Tasigna for treatment of newly diagnosed Ph+ chronic myeloid leukemia. The document contains detailed information about the drug, clinical trial results, safety information, and regulatory approvals. It is not a full financial report, audit report, earnings release, or management discussion. It is a regulatory filing providing material information to investors about a significant regulatory approval and product update. The document length is about 15,000 characters, which is substantial but the content is primarily a press release style announcement rather than a financial or governance report. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2010-12-27 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.